Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lyrica Rivals Are Rolled Out In The US

Executive Summary

Several generic rivals to Pfizer’s Lyrica have hit the US market following the anti-seizure and pain brand’s loss of exclusivity.

You may also be interested in...

Laurus Labs Registers Revenue Record

India’s Laurus Labs reported a strong fourth quarter and financial year on the back of a COVID-19 related demand surge. The company expects the growth rate to continue and improve in the coming quarters.

Pfizer’s Upjohn Business Sees ‘Expected Drop’ Of 37%

Despite reporting a 37% drop in Upjohn’s first-quarter sales, Pfizer has insisted that the decline was consistent with its expectations for the business. Meanwhile, biosimilars sales have been boosted by US launches as sterile injectables and hospital medicines have seen a lift from COVID-19.

Pfizer Delivers On Biosimilars Strategy

Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts